NOV 16, 2017 6:23 AM PST

FDA Approves First Digital Drug That Records Being Taken

WRITTEN BY: Julia Travers

In Nov. 2017, The Food and Drug Administration (FDA) gave approval to Abilify MyCite, an antipsychotic medication, and the first drug to be approved with a digital ingestion tracking system. This means that the pill contains a small embedded sensor that records when it is taken. The pill sends the date and time it is taken to a patch worn by the patient, which sends it to a smartphone app. This is a major development in digital pill-tracking, an area wherein most previous options have centered on bottles that detect whether they are opened.

Abilify MyCite, credit: Proteus Digital Health

"Being able to track ingestion of medications prescribed for mental illness may be useful for some patients," FDA Director of the Division of Psychiatry Products Dr. Mitchell Mathis tells NPR, adding that his organization “is committed to working with companies to understand how technology might benefit patients and prescribers."

Otsuka Pharmaceutical in Japan makes Abilify, which is the brand-name version of the antipsychotic aripiprazole. This medication is often prescribed to people with bipolar disorder, schizophrenia or depression. When one of these individuals takes Abilify MyCite, they ingest a small, grain-sized sensor in the pill. The sensor is made by Proteus Digital Health and becomes active when it hits the stomach fluids.

Dr. Paul Appelbaum, Columbia University’s director of law, ethics and psychiatry in the psychiatry department, tells The New York Times he was surprised to see mental illnesses like schizophrenia be the first conditions to which this high-tech surveillance medicine was applied. "Many of those patients don't take meds because they don't like side effects, or don't think they have an illness, or because they become paranoid about the doctor or the doctor's intentions." Psychiatrist Dr. Peter Kramer warns the Times that this “tattletale” medication “sounds like a potentially coercive tool.”

Patient rights, privacy and confidentiality are prominent themes in any discussion of medical procedure and record, and pill sensors transmitting digital records may bring up unique concerns. "We've seen time and time again that stuff that's being transmitted ends up in the hands of people it shouldn't. There are real concerns about data security," says Dr. Walid Gellad, co-director of the University of Pittsburgh’s Center for Pharmaceutical Policy and Prescribing.

Abilify MyCite label, credit: Otsuka US

While the drug’s methods and the illnesses’ symptoms may be incongruent in some ways, caregivers might be relieved to have the option of knowing whether a loved one is staying on their prescribed course of treatment, Gellad says. Along with easing some minds, the Times reports that reducing nonadherence (noncompliance to prescriptions) could save a lot of money – it costs billions annually, usually because patients end up needing additional care. Nonadherence can be a dangerous issue for patients with many conditions, including high cholesterol and blood pressure issues.

Abilify can also be given in a monthly injection. According to The Wall Street Journal, the smallest amount of the monthly injectable is $1,478 and a monthly supply of nondigital pills "is at least $891.” The cost of the MyCite version has not been released.

The FDA states Abilify MyCite's hasn't been shown to improve patients' compliance and that it “should not be used to track drug ingestion in 'real-time' or during an emergency because detection may be delayed or may not occur."

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech, conservation and the arts. She enjoys solutions journalism. Find more of her work at jtravers.journoportfolio.com.
You May Also Like
JAN 20, 2020
Technology
JAN 20, 2020
Open-Source Software Judges The Accuracy of Cancer Predicting Computer Programs
Cancers are generally composed of diverse cells that vary in genetics—these variations often make a particular can...
JAN 28, 2020
Space & Astronomy
JAN 28, 2020
An Ambitious New Mission to Explore the Sun's Poles
A plethora of spacecraft have photographed the Sun, but every one of those photographs has been snapped from the rather limited perspective of the Sun&rsqu
FEB 02, 2020
Space & Astronomy
FEB 02, 2020
NASA Officially Retires the Spitzer Space Telescope
NASA is always sending spacecraft into space to explore the universe around us; be it the close-proximity stellar neighborhood of our own solar system or o
MAR 02, 2020
Cell & Molecular Biology
MAR 02, 2020
Pushing the Limits of Ribosomes
Researchers engineer mutant ribosomes that can create biopolymers that are not found in nature.
MAR 17, 2020
Technology
MAR 17, 2020
Flat-Panel Technology
Scientists are looking to reinvent mirrors! At least according to research being done at Los Alamos National Laboratory, investigators are looking towards
MAR 29, 2020
Space & Astronomy
MAR 29, 2020
United States Space Force Launches First Mission
Despite all the measures that are currently in place to keep as much of the general public away from public places as possible in this time of COVID-19-cen
Loading Comments...